查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1870844

诊断试剂市场按产品类型、最终用户和应用划分 - 全球预测 2025-2032

Diagnostic Substances Market by Product Type, End-User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，诊断材料市场规模将达到 2,984.7 亿美元，复合年增长率为 6.64%。

关键市场统计数据
基准年 2024 1783.6亿美元
预计年份：2025年 1895.3亿美元
预测年份 2032 2984.7亿美元
复合年增长率 (%) 6.64%

从技术创新、临床效用预期、策略供应链需求三个角度分析当前的诊断环境。

在科学创新、临床实践变革和监管力度加大的推动下，诊断产业正经历快速变革时期。分子诊断、影像技术和高通量检测技术的进步正在重塑临床医生、实验室和研究机构识别和监测疾病的方式。同时，支付方和采购团队也越来越重视临床效用和营运效率的证据，要求製造商和服务提供者证明其产品除了分析效能之外，还具有明确的价值提案。

科学突破、数位整合、不断变化的监管环境以及支付方的需求如何重塑竞争格局和价值创造

科学突破、数位整合以及相关人员期望的转变正在改变医疗格局。精准的分子工具和先进的成像系统能够实现疾病的早期特异性检测，从而推动了对配套试剂盒、检测方法和特殊试剂的需求，以支援标靶工作流程。同时，数位健康平台和实验室资讯系统（LIS）正在改善数据收集和分析，使医疗服务提供者能够利用诊断结果为决策和社区医疗政策提供支援。

评估近期美国关税政策对诊断供应链和采购韧性的营运和策略影响

美国实施的关税政策为营运全球供应链并服务国内终端用户的公司带来了新的挑战。某些类型的检测设备、试剂和进口零件关税的提高增加了到岸成本，促使买家重新评估筹资策略。为此，许多供应商开始改变采购方式，包括供应商多元化、增加区域库存缓衝以及重新谈判供应商合同，以在维持服务水准的同时保护利润率。

透过市场分析，利用跨产品类型、最终用户环境以及临床和研究应用的多层次细分，识别策略转折点。

精细化的细分框架揭示了产品类型、最终用户和应用领域中的竞争优势和未满足的需求。在检验产品类型差异时，仪器可细分为分析仪器、影像设备和分子诊断仪器，其中分子诊断仪器包括次世代定序平台和PCR仪器。试剂盒和检测方法包括ELISA试剂盒、横向流动化验、PCR试剂盒和快速检测套组，每种试剂盒都针对从集中式到分散式检查的不同应用情境。试剂构成一个独立的支柱，包括抗体试剂、抗原试剂、酵素、核酸试剂和重组蛋白，这些试剂共同支撑着检测的性能和可重复性。

比较美洲、欧洲、中东和非洲以及亚太地区的区域趋势和商业化需求，将影响产品的采用和监管应对措施。

区域趋势持续影响美洲、欧洲、中东和非洲以及亚太地区的需求模式、监管方式和投资重点。在美洲，一体化医疗体系和大型实验室网路催生了对可扩展设备、综合检测方案以及支持报销的基于价值的证据的需求。该地区也高度重视公共卫生紧急准备，这影响快速检测套组和高通量分析仪的采购。

主要企业如何协调技术、製造和服务方面的投资，以确保可持续的商业性优势和机构伙伴关係

诊断生态系中的企业正围绕着技术深度、上游试剂管理和以服务为导向的商业化这三大核心构面调整其策略。领先的仪器製造商正投资于平台互通性、软体赋能的诊断技术，并拓展服务组合，以确保与客户建立长期合作关係。同时，专业试剂供应商则专注于高品质的原料和生产的一致性，因为他们意识到，检测结果的可重复性正受到监管机构和临床用户的日益严格的审查。

为行业领导者提供切实可行的策略倡议，以增强韧性、加快普及速度并在诊断领域创造永续的商业性差异化优势

产业领导者应优先采取重点行动，以应对不确定性并抓住策略机会。首先，投资增强製造韧性和供应商多元化，将降低受贸易政策波动和零件短缺的影响，同时保障临床客户的持续供应。其次，加强监管和临床证据建立能力，将加快在复杂司法管辖区的市场进入，并为支付方提供製定医疗决策所需的数据。第三，将数位化功能（从连接和分析到远端监测）嵌入仪器和检测方法中，可以创造持续的收入来源并提高客户维繫。

综合调查方法结合了基础研究、监管分析和价值链分析，以确保获得严谨且检验的洞见。

本分析整合了第一手和第二手研究资料，以提供关于诊断试剂的全面观点。第一手研究资料包括对实验室主任、采购人员、监管专家和产品开发负责人进行的结构化访谈，从而获得关于应用驱动因素、营运挑战和采购重点的实地洞察。这些质性研究资料与二级资讯来源（包括同侪审查文献、监管指导文件和公司备案文件）进行三角验证，以确保事实的严谨性和背景的深度。

最终整合凸显了技术卓越、法规遵循、实际效用之间的协调一致，而这正是未来成功的关键因素。

诊断技术处于技术创新与临床需求的交会点，其近期发展前景将取决于企业如何将产品功能与实际临床和营运需求有效结合。对临床效用、供应链韧性和合规性的日益重视提高了新参与企业的门槛，同时也奖励了那些能够展现端到端可靠性的企业。同时，数位化和整合服务模式正在创造新的触点，以建立超越简单交易的长期客户参与。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 基于 CRISPR 技术的传染病检查诊断剂获得监管部门核准数量激增
  • 扩大照护现场
  • 将人工智慧影像分析技术整合到免疫组织化学诊断中，以改善癌症亚型分类。
  • 加强诊断剂供应商与远端医疗平台之间的合作，以实现远端样本分析
  • 在液态生物检体诊断中采用次世代定序技术进行癌症早期检测
  • 开发用于环境友善照护现场诊断检测的可生物降解微流体晶片
  • 多重免疫检测在自体免疫疾病监测中的应用日益广泛，尤其针对细胞激素谱。
  • 奈米抗体试剂的出现提高了体外免疫检测的灵敏度
  • 精准医疗中，与标靶癌症治疗相关的伴随诊断需求迅速成长。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：诊断试剂市场（依产品类型划分）

  • 装置
    • 分析器
    • 影像设备
    • 分子诊断设备
      • 次世代定序
      • PCR装置
  • 试剂盒和检测
    • ELISA试剂盒
    • 横向流动化验
    • PCR试剂盒
    • 快速检测套组
  • 试剂
    • 抗体试剂
    • 抗原试剂
    • 酵素
    • 核酸试剂
    • 重组蛋白

9. 按最终用户分類的诊断材料市场

  • 诊断实验室
  • 法医科学研究所
  • 医院和诊所
  • 就地检验设施
  • 研究和学术机构

第十章 按应用分類的诊断材料市场

  • 临床诊断
    • 心臟病学
    • 内分泌学
    • 感染疾病
    • 神经病学
    • 肿瘤学
  • 法医学
    • 血液样本检测
    • DNA分析
    • 毒理学
  • 研究
    • 药物发现
    • 基因组研究
    • 蛋白质体学调查

第十一章 各地区诊断材料市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章：按组别分類的诊断材料市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国诊断试剂市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • Agilent Technologies Inc.
    • Asuragen, Inc. by Bio-Techne Corporation
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories Inc.
    • bioLytical Laboratories
    • bioMerieux SA
    • Cepheid by Danaher Corporation
    • DiaSorin SpA
    • Enzo Biochem, Inc.
    • Hitachi Ltd.
    • Hoffmann-La Roche AG
    • Hologic Inc.
    • HyTest Ltd.
    • Illumina Inc.
    • Merck KGaA
    • OraSure Technologies, Inc.
    • Ortho Clinical Diagnostics
    • Qiagen NV
    • Quidel Corporation
    • Randox Laboratories Ltd.
    • Sekisui Diagnostics, LLC
    • Siemens AG
    • Sysmex Corporation by TOA Corporation
    • Thermo Fisher Scientific Inc.
Product Code: MRR-1A1A064C040C

The Diagnostic Substances Market is projected to grow by USD 298.47 billion at a CAGR of 6.64% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 178.36 billion
Estimated Year [2025] USD 189.53 billion
Forecast Year [2032] USD 298.47 billion
CAGR (%) 6.64%

Framing the current diagnostic substances environment by examining technological innovation, clinical utility expectations, and strategic supply chain imperatives

The diagnostic substances arena is undergoing a period of rapid evolution driven by scientific innovation, shifting clinical practice, and heightened regulatory scrutiny. Technological advances in molecular diagnostics, imaging modalities, and high-throughput assay formats are reshaping how clinicians, laboratories, and research organizations identify and monitor disease. At the same time, payers and procurement teams are placing greater emphasis on evidence of clinical utility and operational efficiency, which is prompting manufacturers and service providers to demonstrate clear value propositions beyond analytical performance.

Across laboratory networks and point-of-care settings, operational resilience and supply chain continuity have ascended as strategic priorities. Stakeholders are balancing the imperative to adopt cutting-edge instruments and assays with the need to ensure reproducibility, affordability, and regulatory compliance. Consequently, partnerships among instrument makers, reagent suppliers, and clinical networks are becoming more integrated, with cross-functional collaborations focused on workflow optimization, data interoperability, and lifecycle support. Taken together, these dynamics are recalibrating investment decisions and competitive positioning in diagnostic substances, creating new opportunities for organizations that can translate technical differentiation into measurable clinical and economic outcomes.

How scientific breakthroughs, digital integration, regulatory evolution, and payer demands are collectively reshaping competitive dynamics and value creation

The landscape is being transformed by a confluence of scientific breakthroughs, digital integration, and shifting stakeholder expectations. Precision-focused molecular tools and advanced imaging systems are enabling earlier and more specific detection of disease, which in turn is driving demand for complementary kits, assays, and specialized reagents that can support targeted workflows. Simultaneously, digital health platforms and laboratory information systems are improving data capture and analytics, enabling providers to harness diagnostic outputs for decision support and population health initiatives.

Regulatory frameworks are also evolving to accommodate novel modalities and accelerate review pathways for high-impact diagnostics, which creates both opportunities and compliance challenges for manufacturers. Payers are increasingly requiring evidence of clinical and economic benefit, prompting firms to invest in real-world evidence generation and post-market surveillance. Finally, market participants are responding to procurement pressures by redesigning service models and aftersales support, prioritizing total cost of ownership and uptime guarantees. Collectively, these trends are shifting competitive dynamics toward vertically integrated solutions and strategic alliances that can deliver end-to-end value to laboratories, hospitals, and research institutions.

Assessing the operational and strategic ramifications of recent United States tariff policies on diagnostic supply chains and procurement resilience

Tariff actions implemented in the United States have introduced new layers of complexity for firms operating global supply chains and servicing domestic end-users. Increased duties on specific classes of laboratory instruments, reagents, and imported components have elevated landed costs and prompted buyers to reassess sourcing strategies. In response, many suppliers have initiated changes to procurement, including diversifying supplier bases, increasing regional inventory buffers, and renegotiating supplier contracts to protect margins while preserving service levels.

These shifts have also accelerated conversations around onshoring and nearshoring of critical manufacturing and subassembly capabilities. Manufacturers and contract providers are weighing the trade-offs between higher fixed investments for domestic capacity and the resilience benefits that come from reduced exposure to cross-border tariff volatility. At the same time, downstream stakeholders-diagnostic laboratories, hospitals, and point-of-care providers-are adapting procurement protocols to account for longer lead times and potential component substitution. This environment reinforces the importance of transparent supplier communication, contractual flexibility, and scenario planning to mitigate the cumulative operational impacts of tariff-induced cost pressures while maintaining clinical continuity.

Deconstructing the market through layered segmentation across product types, end-user settings, and clinical and research applications to identify strategic inflection points

A nuanced segmentation framework reveals where competitive advantages and unmet needs are concentrated across product types, end-users, and applications. When examining product type distinctions, instruments are subdivided into analyzers, imaging equipment, and molecular diagnostic instruments, with the latter category encompassing next-generation sequencing platforms and PCR machines. Kits and assays include ELISA kits, lateral flow assays, PCR kits, and rapid test kits, each serving distinct use cases from centralized laboratories to decentralized testing. Reagents form a separate pillar and comprise antibody reagents, antigen reagents, enzymes, nucleic acid reagents, and recombinant proteins, which collectively underpin assay performance and reproducibility.

Turning to end-user segmentation, diagnostic laboratories and forensic laboratories demand high-throughput, validated solutions with robust quality management and chain-of-custody capabilities, whereas hospitals and clinics prioritize integrated workflows and clinician-facing usability. Point-of-care testing facilities emphasize portability, speed, and simplicity, and research and academic institutes focus on versatility and advanced methodological support. Regarding applications, clinical diagnostics spans cardiology, endocrinology, infectious diseases, neurology, and oncology, each with unique biomarker requirements and regulatory pathways. Forensic applications center on blood sample testing, DNA analysis, and toxicology, while research applications include drug discovery, genomics research, and proteomics research. This layered segmentation highlights where product innovation, regulatory navigation, and tailored go-to-market strategies can yield the greatest returns for suppliers and service providers.

Comparative regional dynamics and commercialization imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine adoption and regulatory engagement

Regional dynamics continue to shape demand patterns, regulatory approaches, and investment priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated healthcare systems and large laboratory networks create demand for scalable instrumentation, integrated assay portfolios, and value-based evidence that supports reimbursement. The region also emphasizes public health preparedness, which influences procurement of rapid test kits and high-throughput analyzers.

Europe, Middle East & Africa features a mosaic of regulatory regimes and reimbursement landscapes, where harmonization initiatives coexist with national-level variability. This environment elevates the importance of local regulatory expertise, adaptable product configurations, and partnerships that can navigate fragmented reimbursement pathways. Asia-Pacific is characterized by rapid adoption of molecular diagnostics and point-of-care modalities, driven by large patient volumes, robust research activity, and government-led health modernization programs. Across regions, manufacturers are balancing global platform strategies with localized commercialization tactics to address distinct clinical priorities, regulatory hurdles, and infrastructure constraints.

How leading companies are aligning technological, manufacturing, and service investments to secure durable commercial advantages and institutional partnerships

Company strategies in the diagnostic substances ecosystem are differentiating along axes of technological depth, upstream reagent control, and service-oriented commercialization. Leading instrument manufacturers are investing in platform interoperability, software-enabled diagnostics, and expanded service portfolios to lock in long-term customer relationships. At the same time, specialized reagent providers are focusing on high-quality raw materials and manufacturing consistency, recognizing that reproducibility of assays is increasingly scrutinized by regulators and clinical users.

Strategic partnerships and M&A activity continue to be tools for filling capability gaps, whether to add molecular expertise, expand geographic reach, or secure critical reagent supply lines. Contract manufacturing and co-development agreements are increasingly common, enabling smaller innovators to scale while leveraging established quality systems. Firms that combine robust regulatory pathways, strong technical support, and flexible commercial terms are better positioned to capture long-term institutional contracts and to support multi-site deployments. Overall, the competitive landscape rewards companies that deliver end-to-end value-combining validated chemistry, reliable instruments, and responsive lifecycle services.

Actionable strategic moves for industry leaders to strengthen resilience, accelerate access, and create sustainable commercial differentiation in diagnostics

Industry leaders should prioritize a set of focused actions to navigate uncertainty and capture strategic opportunities. First, investing in manufacturing resilience and supplier diversification can reduce exposure to trade policy shocks and component shortages while supporting continuity for clinical customers. Second, strengthening regulatory and clinical evidence capabilities will accelerate market access in complex jurisdictions and provide payers with the data required for coverage decisions. Third, embedding digital capabilities into instruments and assays-ranging from connectivity and analytics to remote monitoring-can create recurring revenue streams and improve customer retention.

Moreover, companies should pursue targeted collaborations with healthcare providers and academic centers to generate real-world evidence and to refine product-market fit for specialized applications like oncology and genomics research. Commercial teams must also adapt contracting approaches to emphasize service-level agreements and outcome-based elements that resonate with procurement stakeholders. Finally, leaders should maintain agile scenario planning processes to respond quickly to policy shifts and supply chain disruptions, ensuring that operational and commercial tactics remain aligned with evolving market realities.

Comprehensive research methodology combining primary interviews, regulatory analysis, and value-chain mapping to ensure rigorous and validated findings

This analysis synthesizes primary and secondary research streams to deliver a comprehensive perspective on diagnostic substances. Primary inputs include structured interviews with laboratory directors, procurement executives, regulatory specialists, and product development leaders, providing frontline insights into adoption drivers, operational pain points, and procurement priorities. These qualitative inputs were triangulated with secondary sources such as peer-reviewed literature, regulatory guidance documents, and corporate filings to ensure factual rigor and contextual depth.

Analytical approaches included value-chain mapping to identify critical bottlenecks, scenario analysis to evaluate tariff- and supply-related risks, and comparative regional assessments to surface localization requirements. Attention was given to methodological transparency: stakeholders and data sources were chosen to reflect a balance of public and private sector perspectives, and assumptions underlying interpretive judgments are documented in the full report. Where applicable, findings were validated through peer review by subject-matter experts in molecular diagnostics, clinical laboratory operations, and health economics.

Final synthesis emphasizing alignment of technical excellence, regulatory compliance, and real-world utility as the decisive determinants of future success

Diagnostic substances are at the intersection of technological innovation and clinical necessity, and the sector's near-term trajectory will be governed by how well firms align product capabilities with real-world clinical and operational needs. Increasing emphasis on evidence of clinical utility, supply chain resilience, and regulatory adherence is raising the bar for new entrants while rewarding companies that can demonstrate end-to-end reliability. At the same time, digital enablement and integrated service models are creating new touchpoints for long-term customer engagement beyond transactional sales.

To succeed, stakeholders must balance investment in advanced platforms and reagent quality with pragmatic strategies for regional market access and procurement engagement. Proactive collaboration across manufacturers, clinical networks, and regulatory bodies will be essential to streamline adoption pathways and to capture the full potential of diagnostics for patient care and research advancement. Ultimately, organizations that can translate technical differentiation into measurable clinical outcomes and operational value will lead the next wave of growth and adoption in diagnostic substances.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Surge in regulatory approvals for CRISPR-based diagnostic reagents in infectious disease testing
  • 5.2. Expansion of point-of-care molecular diagnostic platforms for antibiotic resistance detection
  • 5.3. Integration of AI-powered image analysis in immunohistochemistry diagnostics to improve cancer subtype classification
  • 5.4. Growing collaboration between diagnostic reagent suppliers and telemedicine platforms for remote sample analysis
  • 5.5. Adoption of next-generation sequencing assays in liquid biopsy diagnostics for early cancer detection
  • 5.6. Development of biodegradable microfluidic chips for eco friendly point-of-care diagnostic testing
  • 5.7. Increased utilization of multiplexed immunoassays targeting cytokine profiles in autoimmune disease monitoring
  • 5.8. Emergence of nanobody-based reagents enhancing sensitivity of in vitro diagnostic immunoassays
  • 5.9. Surging demand for companion diagnostics aligned with targeted oncology therapies in precision medicine

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diagnostic Substances Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Analyzers
    • 8.1.2. Imaging Equipment
    • 8.1.3. Molecular Diagnostic Instruments
      • 8.1.3.1. Next-Generation Sequencing
      • 8.1.3.2. PCR Machines
  • 8.2. Kits & Assays
    • 8.2.1. ELISA Kits
    • 8.2.2. Lateral Flow Assays
    • 8.2.3. PCR Kits
    • 8.2.4. Rapid Test Kits
  • 8.3. Reagents
    • 8.3.1. Antibody Reagents
    • 8.3.2. Antigen Reagents
    • 8.3.3. Enzymes
    • 8.3.4. Nucleic Acid Reagents
    • 8.3.5. Recombinant Proteins

9. Diagnostic Substances Market, by End-User

  • 9.1. Diagnostic Laboratories
  • 9.2. Forensic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Point-of-Care Testing Facilities
  • 9.5. Research & Academic Institutes

10. Diagnostic Substances Market, by Application

  • 10.1. Clinical Diagnostics
    • 10.1.1. Cardiology
    • 10.1.2. Endocrinology
    • 10.1.3. Infectious Diseases
    • 10.1.4. Neurology
    • 10.1.5. Oncology
  • 10.2. Forensic
    • 10.2.1. Blood Sample Testing
    • 10.2.2. DNA Analysis
    • 10.2.3. Toxicology
  • 10.3. Research
    • 10.3.1. Drug Discovery
    • 10.3.2. Genomics Research
    • 10.3.3. Proteomics Research

11. Diagnostic Substances Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Diagnostic Substances Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Diagnostic Substances Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Abbott Laboratories
    • 14.3.2. Agilent Technologies Inc.
    • 14.3.3. Asuragen, Inc. by Bio-Techne Corporation
    • 14.3.4. Becton, Dickinson and Company
    • 14.3.5. Bio-Rad Laboratories Inc.
    • 14.3.6. bioLytical Laboratories
    • 14.3.7. bioMerieux SA
    • 14.3.8. Cepheid by Danaher Corporation
    • 14.3.9. DiaSorin S.p.A.
    • 14.3.10. Enzo Biochem, Inc.
    • 14.3.11. Hitachi Ltd.
    • 14.3.12. Hoffmann-La Roche AG
    • 14.3.13. Hologic Inc.
    • 14.3.14. HyTest Ltd.
    • 14.3.15. Illumina Inc.
    • 14.3.16. Merck KGaA
    • 14.3.17. OraSure Technologies, Inc.
    • 14.3.18. Ortho Clinical Diagnostics
    • 14.3.19. Qiagen N.V.
    • 14.3.20. Quidel Corporation
    • 14.3.21. Randox Laboratories Ltd.
    • 14.3.22. Sekisui Diagnostics, LLC
    • 14.3.23. Siemens AG
    • 14.3.24. Sysmex Corporation by TOA Corporation
    • 14.3.25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. DIAGNOSTIC SUBSTANCES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. DIAGNOSTIC SUBSTANCES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DIAGNOSTIC SUBSTANCES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBST